Hereditary Angioedema in Greece: The first results of the Greek hereditary Angioedema registry

International Archives of Allergy and Immunology

Volumn 164, Issue 4, 2014, Pages 326-332

  Psarros, Fotis ^a   Koutsostathis, Nick ^b   Farmaki, Evangelia ^c   Speletas, Matthaios G ^b   Germenis, Anastasios E ^b  

^a ATHENS NAVAL HOSPITAL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

C1 inhibitor; Disease specific quality of life; Greek hereditary Angioedema registry; Hereditary Angioedema

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ANTIESTROGEN; BRADYKININ; DANAZOL; ICATIBANT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; AWARENESS; CHILD; CONSENSUS; CONTROLLED STUDY; FEMALE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PHYSICIAN; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; REGISTER; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMAS, HEREDITARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CHILD; CHILD, PRESCHOOL; DANAZOL; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; YOUNG ADULT;

EID: 84908583953     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000366276     Document Type: Article

References (43)

1. Zuraw BL: Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
2. Hsu D, Shaker M: An update on hereditary angioedema. Curr Opin Pediatr 2012; 24: 638-646.
3. Bork K, Davis-Lorton M: Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013; 45: 7-16.
4. Gosswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Bork K, Oldenburg J, Muller CR: Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008; 121: 181-188.
5. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M: Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45: 3536-3544.
6. Kaplan A: Type III hereditary angioedema: defined, but not understood. Ann Allergy Asthma Immunol 2012; 109: 153-154.
7. Fernando SL: The nebulous diagnosis of type III hereditary angioedema. Ann Allergy Asthma Immunol 2013; 111: 65-66.
8. Lunn ML, Santos CB, Craig TJ: Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol 2010; 104: 211-214.
9. Lumry WR: Overview or epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care 2013; 19:S103-S110.
10. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498-503.
11. Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ: Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161(suppl 1):3-9.
12. Lumry WR: Management and prevention of hereditary angioedema attacks. Am J Manag Care 2013; 19:S111-S118.
13. Morgan BP: Hereditary angioedema-therapies old and new. N Engl J Med 2010; 363: 581-583.
14. Lumry WR, Castaldo AJ, Vernon MK, Blau-stein MB, Wilson DA, Horn PT: The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-414.
15. Cardarelli W: Managed care implications of hereditary angioedema. Am J Manag Care 2013; 19:S119-S124.
16. Lane CJ, Grant JA, Dougherty D 3rd: Life with hereditary angioedema: then and now. Postgrad Med 2012; 24: 144-151.
17. Papadopoulou-Alataki E, Foerster T, Antari V, Pavlitou-Tsiontsi A, Varlamis G: Molecular diagnosis and management of hereditary angioedema in a Greek family. Int Arch Allergy Immunol 2008; 147: 166-170.
18. Speletas M, Boukas K, Papadopoulou-Alataki E, Tsitsami E, Germenis AE: Hereditary angioedema in Greek families caused by novel and recurrent mutations. Hum Immunol 2009; 70: 925-929.
19. Bowen T, Cicardi M, Farkas H, et al: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
20. Frank MM, Gelfand JA, Atkinson JP: Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580-593.
21. Lunn ML, Santos CB, Craig TJ: Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol 2010; 104: 211-214.
22. Riedl M, Gower RG, Chrvala CA: Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol 2011; 106: 316-322.
23. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498-503.
24. Bygum A: Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-1158.
25. Bork K, Meng G, Staubach P, Hardt J: Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-274.
26. Kesim B, Uyguner ZO, Gelincik A, Mete Gokmen N, Sin AZ, Karakaya G, Erdenen F, Ardeniz O, Ozseker F, Gulbahar O, Colakoʇlu B, Dal M, Buyukozturk S: The Turkish Hereditary Angioedema Pilot Study (TURHAPS): the first Turkish series of hereditary angioedema. Int Arch Allergy Immunol 2011; 156: 443-450.
27. Agostoni A, Cicardi M: Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992; 71: 206-215.
28. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D: C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139: 379-394.
29. Bouillet L, Gompel A: Hereditary angioedema in women: specific challenges. Immunol Allergy Clin North Am 2013; 33: 505-511.
30. Craig TJ: Recent advances in hereditary angioedema self-administration treatment: summary of an International Hereditary Angioedema Expert Meeting. Int Arch Allergy Immunol 2013; 161(suppl 1):26-27.
31. Lumry W, Castaldo AJ, Vernon M, Blaustein MB, Wilson DA, Horn PT: The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity and depression. Allergy Asthma Proc 2010; 31: 407-414.
32. Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Ma-gerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
33. Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ: Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161(suppl 1):3-9.
34. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE: Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 314-320.
35. Landmesser LM, Mariano D: Impact of a selfadministration training and support program on site of care in patients with hereditary angioedema receiving nanofiltered C1 esterase inhibitor for routine prophylaxis. J Manag Care Pharm 2012; 18: 549.
36. Longhurst HJ, Farkas H, Craig T, Aygoren-Pursun E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
37. Cardarelli W: Managed care implications of hereditary angioedema. Am J Manag Care 2013; 19:S119-S124.
38. Poon E, Seed PT, Greaves MW, Kobza-Black A: The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999; 140: 667-671.
39. Huang SW: Results of an on-line survey of patients with hereditary angioedema. Allergy Asthma Proc 2004; 25: 127-131.
40. Bygum A, Andersen KE, Mikkelsen CS: Selfadministration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-151.
41. Prior N, Remor E, Gomez-Traseira C, Lopez-Serrano C, Cabanas R, Contreras J, Campos A, Cardona V, Cimbollek S, Gonzalez-Quevedo T, Guilarte M, de Rojas DH, Marcos C, Rubio M, Tejedor-Alonso MA, Caballero T: Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes 2012; 10: 82.
42. Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, Montauban V, Finck K, Bouee S, Gompel A, Kanny G; French National Reference Center for Hereditary Angioedema (CREAK): Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 2013; 111: 290-294.
43. Speletas M, Szilagyi A, Psarros F, Moldovan D, Magerl M, Kompoti M, Gramoustianou E, Bors A, Mihaly E, Tordai A, Avramouli A, Varga L, Maurer M, Farkas H, Germenis AE: Hereditary angioedema: molecular and clinical differences among european populations. J Allergy Clin Immunol, 2014 (in press).